NDA 008578 · Tilde Sciences
Daraprim
Pyrimethamine · Oral · Dihydrofolate Reductase Inhibitor Antimalarial
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1953
Jan 23, 1953
Approved uses
1
Original approval plus efficacy supplements
Registered trials
195
69 Phase 3, 1 recruiting
FAERS reports
1,270
980 serious, 221 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 7, 2023.
INDICATIONS AND USAGE Treatment of Toxoplasmosis: DARAPRIM is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 1953 Original approval · Type 1 - New Molecular Entity · priority review Label
1 products under this application
- DARAPRIM · PYRIMETHAMINE 25MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pyrimethamine" as an intervention, any sponsor and status, largest first.
- Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in SenegalPivotal-lookingStatus unknown
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT00712374 · 100,000 participants (planned) · Start Sep 2008 · Primary completion Dec 2011
Drug: sulfadoxine-pyrimethamine plus amodiaquine · For: Malaria
Alliance for International Medical ActionAcademic, hospital or other
NCT03035305 · 36,717 participants · Start Aug 2016 · Primary completion Nov 2016
Drug: Seasonal malaria chemoprevention · For: Malaria
Sites: Kolokani Circle, Mali
JSI Research & Training Institute, Inc.Academic, hospital or other
NCT02758353 · 31,493 participants · Start Apr 2015 · Primary completion Nov 2015
Drug: Community distribution of SP · For: Malaria; Stillbirths
- A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African ChildrenPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT02211729 · 22,090 participants · Start May 2014 · Primary completion Dec 31, 2017
Drug: Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin; Sulphadoxine-pyrimethamine + amodiaquine + placebo azithromycin · For: Malaria; Respiratory Infections
Sites: Houndé, Burkina Faso; Bougouni, Mali
- Improving Care Through Azithromycin Research for Infants in AfricaPivotal-lookingCompleted
Barcelona Institute for Global HealthAcademic, hospital or other
NCT04235816 · 20,560 participants · Start Mar 15, 2021 · Primary completion Sep 11, 2025
Drug: Azithromycin; Placebo · For: Child Mortality
Sites: Freetown, Sierra Leone
- Comparison of Two Strategies for the Delivery of IPTcPivotal-lookingCompleted
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT00376155 · 14,000 participants · Start May 2006
Drug: sulfadoxine /pyrimethamine plus amodiaquine · For: Malaria
Sites: Banjul, The Gambia
- Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Burkina FasoPivotal-lookingStatus unknown
Malaria ConsortiumAcademic, hospital or other
NCT05946642 · 13,000 participants (planned) · Start Jul 15, 2023 · Primary completion May 31, 2024
Drug: Sulphadoxine-Pyrimethamine/Amodiaquine; Dihydroartemisinin/Piperaquine (DP) plus Ivermectin (IVM) · For: Malaria
Sites: Ouagadougou, Burkina Faso
- The Community Effectiveness of IPTi in Southern TanzaniaPivotal-lookingStatus unknown
Swiss Tropical & Public Health InstituteAcademic, hospital or other
NCT00152204 · 13,000 participants (planned) · Start Mar 2005 · Primary completion Dec 2007
Drug: Sulfadoxine-pyrimethamine used for IPTi; IPTi · For: Malaria, Falciparum; Anemia
Sites: Dar es Salaam, Tanzania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use164
- nausea134
- vomiting101
- pancytopenia91
- drug ineffective73
- neutropenia72
- pyrexia64
- headache63
- death50
- dizziness50
- acute kidney injury49
- rash49
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 16 |
| 2006 | 13 |
| 2007 | 16 |
| 2008 | 23 |
| 2009 | 27 |
| 2010 | 24 |
| 2011 | 19 |
| 2012 | 18 |
| 2013 | 21 |
| 2014 | 29 |
| 2015 | 26 |
| 2016 | 77 |
| 2017 | 85 |
| 2018 | 128 |
| 2019 | 103 |
| 2020 | 136 |
| 2021 | 107 |
| 2022 | 125 |
| 2023 | 79 |
| 2024 | 72 |
| 2025 | 57 |
| 2026 | 47 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Revisiting the Evidence Base for Modern-Day Practice of the Treatment of Toxoplasmic Encephalitis: A Systematic Review and Meta-Analysis.
Prosty C, Hanula R, Levin Y, et al. · Clin Infect Dis 2023 · Meta-Analysis, Systematic Review
- A Systematic Review and Meta-Analysis of the Efficacy of Anti-Toxoplasma gondii Medicines in Humans.
Wei HX, Wei SS, Lindsay DS, et al. · PLoS One 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Chlorproguanil-dapsone for treating uncomplicated malaria.
Bukirwa H, Garner P, Critchley J · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children.
Chotsiri P, Zongo I, Milligan P, et al. · Nat Commun 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Systematic Review and Meta-Analysis of Seasonal Malaria Chemoprevention.
Thwing J, Williamson J, Cavros I, et al. · Am J Trop Med Hyg 2024 · Meta-Analysis, Systematic Review
- Mefloquine for preventing malaria in pregnant women.
González R, Pons-Duran C, Piqueras M, et al. · Cochrane Database Syst Rev 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Tilde Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.